Myeloid-derived Suppressor Cell and Regulatory T Cell Immune Monitoring of Soft Tissue Sarcoma Patients Undergoing Combination External Beam Radiation and Intratumoral Dendritic Cell Vaccination

2010 ◽  
Vol 78 (3) ◽  
pp. S657-S658 ◽  
Author(s):  
C.D. Iclozan ◽  
M.J. Cotter ◽  
R. Ramakrishnan ◽  
B.C. Lenox ◽  
M.M. Bui ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Suppressor Cell ◽  
Immune Monitoring ◽  
External Beam Radiation ◽  
Dendritic Cell Vaccination ◽  
External Beam ◽  
Beam Radiation ◽  
Myeloid Derived Suppressor Cell

Low-Dose Neoadjuvant External Beam Radiation Therapy for Soft Tissue Sarcoma

2011 ◽  
Vol 80 (3) ◽  
pp. 779-786 ◽  
Author(s):  
Kiran Devisetty ◽  
Wendy Kobayashi ◽  
Herman D. Suit ◽  
Saveli I. Goldberg ◽  
Andrzej Niemierko ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Low Dose ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation

scholarly journals Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma

Sarcoma ◽  
2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Shailaja Raj ◽  
Marilyn M. Bui ◽  
Gregory Springett ◽  
Anthony Conley ◽  
Sergio Lavilla-Alonso ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Neoadjuvant Treatment ◽  
Soft Tissue Sarcomas ◽  
External Beam Radiation ◽  
Serious Adverse Events ◽  
Clinical Safety ◽  
Beam Radiation ◽  
Clinical Responses

Purpose. Patients with large >5 cm, high-grade resectable soft tissue sarcomas (STS) have the highest risk of distant metastases. Previously we have shown that dendritic cell (DC) based vaccines show consistent immune responses.Methods. This was a Phase I single institution study of neoadjuvant radiation with DC injections on 18 newly diagnosed high-risk STS patients. Neoadjuvant treatment consisted of 50 Gy of external beam radiation (EBRT), given in 25 fractions delivered five days/week, combined with four intratumoral injections of DCs followed by complete resection. The primary endpoint was to establish the immunological response to neoadjuvant therapy and obtain data on its clinical safety and outcomes.Results. There were no unexpected toxicities or serious adverse events. Twelve out of 18 (67%) patients were alive, of which an encouraging 11/18 (61%) were alive with no systemic recurrence over a period of 2–8 years. Favorable immunological responses correlated with clinical responses in some cases.Conclusions. This study provides clinical support to using dendritic cell injections along with radiation in sarcomas, which when used optimally in combination can help clinical outcomes in soft tissue sarcoma. Study registration number isNCT00365872.

External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis

2017 ◽  
Vol 25 (3) ◽  
pp. 754-767 ◽  
Author(s):  
Markus Albertsmeier ◽  
Alexandra Rauch ◽  
Falk Roeder ◽  
Sandro Hasenhütl ◽  
Sebastian Pratschke ◽  
...  
Keyword(s):  
Systematic Review ◽  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Meta Analysis ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation

Perioperative high-dose-rate interstitial brachytherapy combined with external beam radiation therapy for soft tissue sarcoma

Brachytherapy ◽  
2015 ◽  
Vol 14 (4) ◽  
pp. 571-577 ◽  
Author(s):  
Daya Nand Sharma ◽  
S.V. Suryanarayana Deo ◽  
Goura Kisor Rath ◽  
Nootan Kumar Shukla ◽  
Sameer Bakhshi ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Dose Rate ◽  
High Dose Rate ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
High Dose ◽  
External Beam ◽  
Beam Radiation
Sign in / Sign up

Export Citation Format

Share Document